Avacta Group Affimer Drug Conjugates a reality

Hardman & Co Report Report DownloadsAvacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. In addition, Avacta is using external collaborations to expand the opportunities for its Affimer technology. A proof-of-concept study combining its Affimer technology with Glythera’s Permalink chemistry to generate Affimer Drug Conjugates has concluded successfully.

Strategy: To commercialise its Affimer technology through a combination of bespoke research tools, collaborative deals and by identifying and developing its own proprietary therapeutic Affimer leads. Avacta has sufficient cash resources to identify an Affimer lead to be ready for first-in-man in 2019.

Affimer Drug Conjugates (AfDC): Drug conjugation is an approach to get cytotoxic drugs targeted directly at cancer cells. In July 2016, Avacta tied-up with Glythera to combine the advantages of Affimers with Glythera’s chemistry to develop AfDC in an attempt to overcome these problems.

Proof-of-concept study: This study has demonstrated that Avacta’s Affimer technology can be combines successfully with Glythera’s Permalink chemistry to generate AfDC that not only eliminate the well documented disadvantages of ADC, but also to generate a technically superior drug conjugate platform.

Licensing deal: As a consequence of the study outcome, Avacta and Glythera have signed a licensing deal for the further development of their respective proprietary technologies to generate a clinic-ready AfDC drug. Avacta would receive milestones and royalties on the sales of any regulatory approved drug.

Investment summary: Avacta Group Plc has made considerable progress towards its goal of having its own proprietary Affimer-based drugs and growing a profitable reagents business. By itself, AVCT has identified potential leads and completed both in vitro and in vivo pharmacokinetic pre-clinical tests, efficacy and immunogenicity tests. The Glythera collaboration provides another platform on which Avacta could generate long-term returns for shareholders.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is